Abstract:Drug-induced liver injury (DILI) remains a challenge when translating knowledge from the preclinical stage to human use cases. Attempts to model human DILI directly based on the information from drug labels have had some success; however, the approach falls short of providing insights or addressing uncertainty due to the difficulty of decoupling the idiosyncratic nature of human DILI outcomes. Our approach in this comparative analysis is to leverage existing preclinical and clinical data as well as information on metabolism to better translate mammalian to human DILI. The human DILI knowledge base from the United States Food and Drug Administration (U.S. FDA) National Center for Toxicology Research contains 1036 pharmaceuticals from diverse therapeutic categories. A human DILI training set of 305 oral marketed drugs was prepared and a binary classification scheme applied. The second knowledge base consists of mammalian repeated dose toxicity with liver toxicity data from various regulatory sources. Within this knowledge base, we identified 278 pharmaceuticals containing 198 marketed or withdrawn oral drugs with data from the U.S. FDA new drug application and 98 active pharmaceutical ingredients from ToxCast. From this collection, a set of 225 oral drugs was prepared as the mammalian hepatotoxicity training set with particular end points of pathology findings in the liver and bile duct. Both human and mammalian data sets were processed using various learning algorithms, including artificial intelligence approaches. The external validations for both models were comparable to the training statistics. These data sets were also used to extract species-differentiating chemotypes that differentiate DILI effects on humans from mammals. A systematic workflow was devised to predict human DILI and provide mechanistic insights. For a given query molecule, both human and mammalian models are run. If the predictions are discordant, both metabolites and parents are investigated for quantitative structure-activity relationship and species-differentiating chemotypes. Their results are combined using the Dempster-Shafer decision theory to yield a final outcome prediction for human DILI with estimated uncertainty. Finally, these tools are implementable within an in silico platform for systematic evaluation.

Application of advanced in silico methods for predictive modeling and information integration

Role of in silico genotoxicity tools in the regulatory assessment of pharmaceutical impurities

A review on machine learning methods for in silico toxicity prediction

In silico toxicology: computational methods for the prediction of chemical toxicity

In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects

In Silico Methods for Predicting Drug–drug Interactions with Cytochrome P-450s, Transporters and Beyond

The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery

A Review on the Recent Applications of Deep Learning in Predictive Drug Toxicological Studies.

Recent Advances in Omics, Computational Models, and Advanced Screening Methods for Drug Safety and Efficacy

Understanding and overcoming the technical challenges in using in silico predictions in regulatory decisions of complex toxicological endpoints - A pesticide perspective for regulatory toxicologists with a focus on machine learning models

Applications of In Silico Models to Predict Drug-Induced Liver Injury

Tackling the challenges of new approach methods for predicting drug effects from model systems

In silico ADME-Tox modeling: progress and prospects

In Silico Prediction Of Adverse Drug Reactions And Toxicities Based On Structural, Biological And Clinical Data

Predictive Systems Toxicology

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

Artificial Intelligence-Based Toxicity Prediction of Environmental Chemicals: Future Directions for Chemical Management Applications.

Artificial Intelligence for Drug Toxicity and Safety

Open access in silico tools to predict the ADMET profiling of drug candidates

Development of a Battery of In Silico Prediction Tools for Drug-Induced Liver Injury from the Vantage Point of Translational Safety Assessment.

Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction